Amended Current Report Filing (8-k/a)
10 Dezember 2018 - 9:14PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K/A
Amendment
No. 1
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 17, 2018
OptimizeRx Corporation
(Exact name of registrant as specified in its charter)
Nevada
|
|
000-53605
|
|
26-1265381
|
(State
or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification No.)
|
400
Water Street, Suite 200, Rochester, MI
|
|
48307
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
248.651.6568
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory
Note
On
October 17, 2018, we filed a Current Report on Form 8-K to disclose entering into a Stock Purchase Agreement (the “Agreement”)
with, among others, CareSpeak Communications, Inc., a New Jersey corporation, described in Item 1.01 to that report. This Amendment
to the Current Report on Form 8-K is filed to provide the required financial statements of the business acquired and pro forma
financial information.
SECTION
1 - REGISTRANT'S BUSINESS AND OPERATIONS
ITEM
1.01 - ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On
October 17, 2018, OptimizeRx Corp. (the “Company”) entered into, and consummated the transactions contemplated by,
a Stock Purchase Agreement (the “Purchase Agreement”) by and among the Company, CareSpeak Communications, Inc., a
New Jersey corporation (“CareSpeak”) the selling shareholders of CareSpeak (collectively, the “Sellers”),
each of Srdjan Loncar, United Healthcare Services, Inc., Christopher DiCostanzo and Kresimir Nesek as “Seller Indemnitors”
and Srdjan Loncar in his capacity as seller’s representative, which agreement provided for the purchase of all of the equity
of CareSpeak by the Company.
The
consideration for the acquisition consists of $5.5 million in cash, as adjusted for estimated working capital, estimated indebtedness,
escrow amounts and Sellers’ estimated transaction expenses, as well as shares of the Company’s common stock equal
to $500,000 divided by the VWAP for the thirty (30) trading day period ending the day prior to Closing, and earnout payments of
up to $3 million, if any become payable, as a result of achieving certain revenue targets for 2019 and 2020. In addition, the
Company incurred its own expenses for the transaction at approximately $500,000.
On
a standalone basis, CareSpeak is expected to have revenues in excess of $1.0 million in 2018 and be profitable at that level.
Only the portion of that revenue recognized from October 17, 2018 through December 31, 2018 will be reflected in our consolidated
financial statements.
The
Purchase Agreement also contains certain restrictive covenants whereby Sellers are prohibited from (a) competing with the business
of the Company, (b) soliciting employees of the Company and (c) intentionally interfering with the Company’s business relationships,
in each case during the four-year period immediately following the Closing Date.
The
Purchase Agreement contains customary representations and warranties of the parties, including, among others, with respect to
corporate organization, capitalization, corporate authority, financial statements and compliance with applicable laws. The representations
and warranties of each party set forth in the Purchase Agreement were made solely for the benefit of the other parties to the
Purchase Agreement, and investors are not third-party beneficiaries of the Purchase Agreement. In addition, such representations
and warranties (a) are subject to materiality and other qualifications contained in the Purchase Agreement, which may differ from
what may be viewed as material by investors, (b) were made only as of the date of the Purchase Agreement or such other date as
is specified in the Purchase Agreement and (c) may have been included in the Purchase Agreement for the purpose of allocating
risk between the parties rather than establishing matters as facts. Accordingly, the Purchase Agreement is included with this
filing only to provide investors with information regarding the terms of the Purchase Agreement, and not to provide investors
with any other factual information regarding any of the parties or their respective businesses.
The
foregoing description of the Purchase Agreement is not complete and is qualified in its entirety by reference to the text of such
document, which is filed as Exhibit 2.1 hereto and which is incorporated herein by reference.
Section
2 - Financial Information
Item
2.01 Completion of Acquisition or Disposition of Assets.
On
October 17, 2018, the Company completed the acquisition of CareSpeak. As a result of the Closing, CareSpeak became a wholly-owned
subsidiary of the Company. Please refer to Item 1.01 above for addition information about the acquisition.
SECTION
8 – OTHER EVENTS
Item
8.01 Other Events
On
October 17, 2018, we issued a press release concerning the acquisition of CareSpeak. A copy of the press release is attached as
Exhibit 99.1 to this Current Report on Form 8-K.
The
information in Item 8.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
SECTION
9 –
Financial Statements and Exhibits
Item
9.01 Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired. The financial
statements of CareSpeak required by Item 9.01(a) to this Current Report on Form 8-K are filed as exhibits 99.2 and 99.3.
(b) Pro Forma Financial Information. The pro forma financial
information required by Item 9.01(b) to this Current Report on Form 8-K are filed as exhibit 99.4.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OptimizeRx Corporation
|
|
|
Date December 10, 2018
|
/s/
Douglas Baker
|
|
Douglas Baker
|
|
Chief Financial Officer
|
4
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
OptimizeRx (NASDAQ:OPRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024